myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home (NCT05204888)
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home - a Multi-center Randomized Controlled Trial
🩺 Plain-English Summary (8th-Grade Level)
Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks.
Who can join: Review the eligibility criteria below.
Location: UAB School of Medicine/Lung Health Center — Birmingham, Alabama
Age range: 30 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (27 Sites)
Showing the first 25 of 27 sites.
- UAB School of Medicine/Lung Health Center — Birmingham, Alabama
- Honor Health — Scottsdale, Arizona
- University of Florida, Jacksonville — Jacksonville, Florida
- Alloy Clinical Research — Kissimmee, Florida
- Reliable Research, Inc. — Miami, Florida
- NewGen Health Group — Miami, Florida
- Destiny Research — Palmetto Bay, Florida
- University of Chicago — Chicago, Illinois
- The Iowa Clinic — West Des Moines, Iowa
- University of Maryland - Baltimore — Baltimore, Maryland
- Tufts Medical Center — Boston, Massachusetts
- Lahey Hospital and Medical Center — Burlington, Massachusetts
- Henry Ford Health — Detroit, Michigan
- University of Minnesota — Minneapolis, Minnesota
- Cincinnati VA Medical Center — Cincinnati, Ohio
- Cleveland Clinic Foundation — Cleveland, Ohio
- Ohio State University Wexner Medical Center — Columbus, Ohio
- St. Luke's University Health Network — Bethlehem, Pennsylvania
- Clinical Research Associates of Central Pennsylvania — DuBois, Pennsylvania
- Jeanes Hospital — Philadelphia, Pennsylvania
- Temple University — Philadelphia, Pennsylvania
- The University of Pittsburgh — Pittsburgh, Pennsylvania
- Respire Research Institute — Houston, Texas
- The University of Vermont Medical Center, Inc — Burlington, Vermont
- West Virginia Clinical and Translational Science Institute — Morgantown, West Virginia
📞 Contact the Study Coordinator
Phone: (215) 707-8113
Email: Gerard.Criner@tuhs.temple.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in COPD
- Aiding COPD and CHF Ultrasound-guided Management Through ENhanced Point Of Care UltraSound — Calgary,
- Impairments That Affect Correct Inhaler Use in COPD — Birmingham, Alabama
- The Development of an Integrated Physical Activity and Mental Health Intervention for Veterans With COPD, Emotion Distress, and Low Physical Activity — Boston, Massachusetts
- A Study to Evaluate Solrikitug in Participants With COPD (ZION) — Birmingham, Alabama
- RELVAR Effects on Parasternal Muscle Activity, Diaphragm, and Ventilation in Severe COPD — Calgary, Alberta
- Evaluation of the Safety and Efficacy of TLD in Patients with COPD — Birmingham, Alabama
Explore by condition: All COPD clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.